Turning the focus to advanced-stage HCC, Tanios S. Bekaii-Saab, MD, offers comprehensive insights on first- and second-line treatment options.
Zanzalintinib Combo Improves Survival Vs Regorafenib in Metastatic CRC
Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
FDA Limits Pembrolizumab/Nivolumab in PD-L1–Low Gastric Cancer Indications
Subgroup analyses from the phase 3 CheckMate649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
Nadunolimab Earns FDA Fast-Track Designation in Metastatic PDAC
The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.
Adverse Sexual Health Outcomes Appear More Likely in Women With CRC
In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.